Skip to main content
Novartis
language-selector-globe United States | en
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe us
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Novartis in the US 
        • Diversity equity & inclusion  
        • Pay transparency-EPIC 
        • Our code of ethics 
      • Diversity, equity & inclusion  
        • Novartis US EEO / D&I report 2021 
        • Supplier diversity 
      • People and culture 
      • Products 
      • US Country Coordinating Committee 
      • External funding 
      • Contact us 
      Team meeting About
    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Patient assistance 
      • Diseases 
        • Chronic spontaneous urticaria (CSU) 
        • Hidradenitis suppurativa (HS) 
        • Prostate Cancer (PC) 
        • Paroxysmal Nocturnal Hemoglobinuria (PNH) 
      • Participating in clinical trials 
      • Patient perspectives 
      • Adverse event reporting 
      • The STEP program 
        • Sickle cell disease (SCD) 
        • Program overview 
        • Multiple sclerosis (MS) 
        • Cancer 
        • Application for funding to help address health disparities 
        • Health disparities 
      • Patient resources 
      Patient smiling at doctor image Patients and caregivers
    • Healthcare professionals 
      • Novartis pipeline 
      • Novartis clinical trials 
      • Adverse event reporting 
      • HCP resources 
      • Personalized and Precision Medicine 
      • Health Information Technology Resources 
      Two doctors examining X-ray Healthcare professionals
    • ESG 
      • Ethical behavior 
        • Code of ethics 
        • SpeakUp 
        • PhRMA Code on interactions with healthcare professionals 
        • Business principles 
      • Ethics, risk and compliance 
        • Compliance program 
        • State laws 
        • Corporate integrity agreement 
        • Payments to HCPs & HCOs 
        • Drug Supply Chain Security Act Information 
      • Corporate responsibility 
        • Population health 
        • Novartis in society US reports 
        • Novartis US Foundation 
        • Environmental sustainability 
        • People and communities 
      • Beacon of hope 
        • Beacon of hope: Measurable solutions for health equity 
        • Paving the way for a brighter, more equitable future 
      Novartis East Hanover Campus Landscaping ESG
    • News 
      • News archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting News
    • Careers 
      • Career search 
      • Meet the teams 
      • Early career 
      • Personal growth 
      • How we work 
      • Employee benefits 
      • Diversity, equity & inclusion 
      • Awards & recognition 
      Meeting in Atrium Careers
    Grandmother, mother and daughter smiling and laughing on a beach Home
  1. Home
  2. Careers
  3. Career Search
  • Sort by Sort ascending
  • Job Title
  • Site
  • Location
  • Division Sort ascending
  • Business
  • Functional Area
  • Date Posted
Job Title Site Location Division Sort ascending Business Functional Area Date Posted
Corporate Tax Manager Amiria Egypt Finance Corporate Audit & Finance May 31, 2024
P2P & T&E Specialist (Japanese speaker) Selangor Malaysia Finance CTS Audit & Finance Jun 05, 2024
Tax Specialist (m/w/d) Schaftenau Austria Finance CTS Audit & Finance Jul 22, 2024
Procure to Pay Senior Specialist MR11 INSURGENTES Mexico Finance CTS Audit & Finance Jul 23, 2024
Order to Cash Radioligand Therapy Sr. Specialist INSURGENTES Mexico Finance CTS Audit & Finance Aug 06, 2024
Record to Report Specialist INSURGENTES Mexico Finance CTS Audit & Finance Sep 05, 2024
Order Management Specialist - Temporary INSURGENTES Mexico Finance CTS Audit & Finance Sep 25, 2024
Global FC&C Process Expert (Senior Manager) PIN-PCA Prague Czech Republic Finance CTS Audit & Finance Oct 03, 2024
P2P Service Delivery (SD) Lead NGSC INSURGENTES Mexico Finance CTS Audit & Finance Oct 07, 2024
Finance Control and Compliance US Manager INSURGENTES Mexico Finance CTS Audit & Finance Oct 08, 2024
General Accounting Manager INSURGENTES Mexico Finance CTS Audit & Finance Oct 09, 2024
Procure to Pay Business Partner Management INSURGENTES Mexico Finance CTS Audit & Finance Oct 16, 2024
LDC Solution Design Manager RDF Prague Czech Republic Finance CTS Audit & Finance Oct 21, 2024
Finančni analitik poslovnega planiranja in analiz (m/ž/d) / BPA Finance Analyst (m/f/d) Ljubljana Slovenia Finance Innovative Medicines Audit & Finance Oct 21, 2024
Senior Financial Analyst - FC&C Hyderabad (Office) India Finance CTS Audit & Finance Oct 22, 2024
Analitik (m/ž/d) / FRA Analyst (m/f/d) Ljubljana Slovenia Finance CTS Audit & Finance Oct 23, 2024
Manager - FC&C Hyderabad (Office) India Finance CTS Audit & Finance Oct 23, 2024
Analitik (m/ž/d) / FRA Analyst (m/f/d) Ljubljana Slovenia Finance CTS Audit & Finance Oct 23, 2024
Analitik (m/ž/d) / FRA Analyst (m/f/d) Ljubljana Slovenia Finance CTS Audit & Finance Oct 23, 2024
Record to Report Sr. Specialist USA INSURGENTES Mexico Finance CTS Audit & Finance Oct 23, 2024
Senior Product Manager, Digital Finance Barcelona Gran Vía Spain Finance Corporate Audit & Finance Oct 22, 2024
R2R Specialist - GL & Reporting Selangor Malaysia Finance CTS Audit & Finance Oct 15, 2024
FRA Analyst Treasury and Cash Management / Analitik - specialist Ljubljana Slovenia Finance CTS Audit & Finance Oct 15, 2024
R2R Team Lead - GL & Reporting Selangor Malaysia Finance CTS Audit & Finance Oct 10, 2024
Record to Report (R2R) Specialist New Cairo Egypt Finance CTS Audit & Finance Oct 18, 2024
Record to Report (R2R) Section Head New Cairo Egypt Finance CTS Audit & Finance Oct 18, 2024
Associate, Record-to-Report Head Office (Japan) (Pharmaceuticals) Japan Finance CTS Audit & Finance Jun 26, 2024
Revenue Accounting Manager Shanghai (Shanghai) China Finance CTS Audit & Finance Jul 17, 2024
Ethics, Risk & Compliance Manager Selangor Malaysia Ethics Risk & Compliance Innovative Medicines Legal & Intellectual Property & Compl. Aug 22, 2024
Sr Manager/Manager-Monitoring Shanghai (Shanghai) China Ethics Risk & Compliance Innovative Medicines Legal & Intellectual Property & Compl. Jul 18, 2024
Head DPDAI China Shanghai (Shanghai) China Ethics Risk & Compliance Innovative Medicines Legal & Intellectual Property & Compl. Oct 14, 2024
Manager- Data Privacy Review and Remediation Selangor Malaysia Ethics Risk & Compliance Corporate Legal & Intellectual Property & Compl. Oct 14, 2024
Associate Director ERC Risk&Operations, Corporate Functions Selangor Malaysia Ethics Risk & Compliance Corporate Legal & Intellectual Property & Compl. Aug 29, 2024
Risk & Assurance Manager Mumbai (Head Office) India Ethics Risk & Compliance Innovative Medicines Legal & Intellectual Property & Compl. Oct 16, 2024
Country ERC Head, India Mumbai (Office) India Ethics Risk & Compliance Innovative Medicines Legal & Intellectual Property & Compl. Oct 16, 2024
Study Leader Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Sep 05, 2024
Head Regulatory Writing Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Oct 07, 2024
Clinical Research Associate Beijing (Beijing) China Development Innovative Medicines Research & Development Oct 09, 2024
Japan Program Head (Neuroscience & GTx) Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Oct 16, 2024
Japan Program Head (Immunology) Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Oct 16, 2024
Manager, TRD Project management Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Oct 16, 2024
Associate Clinical Project Manager Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Oct 18, 2024
SSO Feasibility Manager Head Office (Japan) (Pharmaceuticals) Japan Development Innovative Medicines Research & Development Oct 21, 2024
RA Operational Excellence Junior Associate – MEA Dubai Utd.Arab Emir. Development Innovative Medicines Research & Development Oct 16, 2024
Country Patient Safety Head - France Paris Headquarter (Novartis Pharma S.A.S.) France Development Innovative Medicines Research & Development Oct 17, 2024
Senior Expert Technical Development- Drug Product Project Lead East Hanover USA Development Innovative Medicines Research & Development Oct 17, 2024
Vendor Alliance Lead Associate Director (Remote) East Hanover USA Development Innovative Medicines Research & Development Oct 17, 2024
Global Program Safety Lead - Immunology Basel (City) Switzerland Development Innovative Medicines Research & Development Oct 17, 2024
Global Program Safety Lead - Immunology London (The Westworks) United Kingdom Development Sandoz Research & Development Oct 17, 2024
Strategy Director, Clinical Development Basel (City) Switzerland Development Innovative Medicines Research & Development Oct 17, 2024

Pagination

  • ‹ Previous page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 42
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & caregivers
  • Healthcare professionals
  • ESG
  • News
  • Careers
Media center
  • News archive
  • Statements
  • Stories
Our portfolio
  • Novartis clinical pipeline
  • Novartis product portfolio
Other Novartis US websites
  • Oncology HCP resources
  • Medical information
  • Global site
Footer Bottom
© 2024 Novartis Pharmaceuticals Corporation
  • Terms of use
  • Privacy policy
  • Consumer health privacy policy
  • Contacts
  • Site map
  • Web accessibility
Novartis Site Directory
This site is intended for US residents only